GSK3B and Parkinson disease: In additional in vitro studies, in line with compelling evidence for a linkage between Wnt/β-catenin signaling and inflammatory events during PD progression, as well as GSK-3β upregulation and β-catenin degradation, compound 69 prevented 6-OHDA-induced cell death by inhibiting GSK-3β, and promoted β-catenin stabilization, thus restoring its neuroprotective potential [158].